☰

Shannon E. Boye - Publications

Affiliations: 
University of Florida, Gainesville, Gainesville, FL, United States 
Area:
retinal gene therapy, ocular gene therapy, inherited retinal degenerations, leber congenital amaurosis, AAV, photoreceptors
Tree Info Similar researchers PubMed Report error

65 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Kellish PC, Marsic D, Crosson SM, Choudhury S, Scalabrino ML, Strang CE, Hill J, McCullough KT, Peterson JJ, Fajardo D, Gupte S, Makal V, Kondratov O, Kondratova L, Iyer S, ... ... Boye SL, ... ... Boye SE, et al. Intravitreal injection of a rationally designed AAV capsid library in non-human primate identifies variants with enhanced retinal transduction and neutralizing antibody evasion. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 37814449 DOI: 10.1016/j.ymthe.2023.10.001  0.809
2023 Lau SC, Grati M, Isgrig K, Sinan M, Calabro KR, Zhu J, Ishibashi Y, Ozgur Z, Wafa T, Belyantseva IA, Fitzgerald T, Friedman TB, Boye SL, Boye SE, Chien WW. Dual-AAV vector-mediated expression of improves vestibular function in a mouse model of Usher syndrome 1B. Molecular Therapy. Methods & Clinical Development. 30: 534-545. PMID 37693946 DOI: 10.1016/j.omtm.2023.08.012  0.384
2023 Calabro KR, Boye SL, Boye SE. Optimization of Capillary-Based Western Blotting for MYO7A. Advances in Experimental Medicine and Biology. 1415: 125-130. PMID 37440024 DOI: 10.1007/978-3-031-27681-1_19  0.348
2023 Mellen RW, Calabro KR, McCullough KT, Crosson SM, Cova A, Fajardo D, Xu E, Boye SL, Boye SE. Development of an AAV-CRISPR-Cas9-based treatment for dominant cone-rod dystrophy 6. Molecular Therapy. Methods & Clinical Development. 30: 48-64. PMID 37361352 DOI: 10.1016/j.omtm.2023.05.020  0.447
2023 Periasamy R, Patel DD, Boye SL, Boye SE, Lipinski DM. Improving retinal vascular endothelial cell tropism through rational rAAV capsid design. Plos One. 18: e0285370. PMID 37167304 DOI: 10.1371/journal.pone.0285370  0.453
2022 Boye SL, O'Riordan C, Morris J, Lukason M, Compton D, Baek R, Elmore DM, Peterson JJ, Fajardo D, McCullough KT, Scaria A, McVie-Wylie A, Boye SE. Preclinical studies in support of phase I/II clinical trials to treat -associated Leber congenital amaurosis. Molecular Therapy. Methods & Clinical Development. 28: 129-145. PMID 36654798 DOI: 10.1016/j.omtm.2022.12.007  0.401
2022 Jacobson SG, Cideciyan AV, Ho AC, Roman AJ, Wu V, Garafalo AV, Sumaroka A, Krishnan AK, Swider M, Mascio AA, Kay CN, Yoon D, Fujita KP, Boye SL, Peshenko IV, ... ... Boye SE, et al. Night vision restored in days after decades of congenital blindness. Iscience. 25: 105274. PMID 36274938 DOI: 10.1016/j.isci.2022.105274  0.383
2022 Deng WT, Ma X, Sechrest E, Fajardo D, Zhu P, Dyka FM, Wang Y, Lobanova E, Boye S, Baehr W. Gene Therapy in Opn1mw-/-/Opn1sw-/- Mice and Implications for Blue Cone Monochromacy Patients with Deletion Mutations. Human Gene Therapy. PMID 35272502 DOI: 10.1089/hum.2021.298  0.45
2021 Jacobson SG, Cideciyan AV, Ho AC, Peshenko IV, Garafalo AV, Roman AJ, Sumaroka A, Wu V, Krishnan AK, Sheplock R, Boye SL, Dizhoor AM, Boye SE. Safety and improved efficacy signals following gene therapy in childhood blindness caused by mutations. Iscience. 24: 102409. PMID 33997691 DOI: 10.1016/j.isci.2021.102409  0.411
2021 Crosson SM, Bennett A, Fajardo D, Peterson JJ, Zhang H, Li W, Leahy MT, Jennings CK, Boyd RF, Boye SL, Agbandge-McKenna M, Boye SE. Effects of Altering HSPG Binding and Capsid Hydrophilicity on Retinal Transduction by AAV. Journal of Virology. PMID 33658343 DOI: 10.1128/JVI.02440-20  0.568
2020 Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M, Byrne BJ, Tremblay JP. Current Clinical Applications of in vivo Gene Therapy with AAVs. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33309881 DOI: 10.1016/j.ymthe.2020.12.007  0.364
2020 Gilkes JA, Judkins BL, Herrera BN, Mandel RJ, Boye SL, Boye SE, Srivastava A, Heldermon CD. Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse. Gene Therapy. PMID 33244179 DOI: 10.1038/s41434-020-00206-w  0.307
2020 Sasaki Y, Kakita H, Kubota S, Sene A, Lee TJ, Ban N, Dong Z, Lin JB, Boye SL, DiAntonio A, Boye SE, Apte RS, Milbrandt J. SARM1 depletion rescues NMNAT1-dependent photoreceptor cell death and retinal degeneration. Elife. 9. PMID 33107823 DOI: 10.7554/eLife.62027  0.399
2020 Boye SL, Choudhury S, Crosson S, Di Pasquale G, Afione S, Mellen R, Makal V, Calabro KR, Fajardo D, Peterson J, Zhang H, Leahy MT, Jennings CK, Chiorini JA, Boyd RF, ... Boye SE, et al. Novel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32304666 DOI: 10.1016/J.Ymthe.2020.04.002  0.665
2020 Goodwin MS, Croft CL, Futch HS, Ryu D, Ceballos-Diaz C, Liu X, Paterno G, Mejia C, Deng D, Menezes K, Londono L, Arjona K, Parianos M, Truong V, Rostonics E, ... ... Boye SL, ... ... Boye SE, et al. Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS. Molecular Neurodegeneration. 15: 15. PMID 32122372 DOI: 10.1186/S13024-020-00361-Z  0.47
2019 Calabro KR, Boye SL, Choudhury S, Fajardo D, Peterson JJ, Li W, Crosson SM, Kim MJ, Ding D, Salvi R, Someya S, Boye SE. A Novel Mouse Model of USH1B Reveals Auditory and Visual System Haploinsufficiencies. Frontiers in Neuroscience. 13: 1255. PMID 31824252 DOI: 10.3389/Fnins.2019.01255  0.477
2019 Gamlin PD, Alexander JJ, Boye SL, Witherspoon CD, Boye SE. SubILM Injection of AAV for Gene Delivery to the Retina. Methods in Molecular Biology (Clifton, N.J.). 1950: 249-262. PMID 30783978 DOI: 10.1007/978-1-4939-9139-6_14  0.63
2018 McCullough KT, Boye SL, Fajardo D, Calabro KR, Peterson JJ, Strang CE, Chakraborty D, Gloskowski S, Haskett S, Samuelsson S, Jiang H, Witherspoon CD, Gamlin PD, Maeder ML, Boye S. Somatic gene editing of GUCY2D by AAV-CRISPR/Cas9 alters retinal structure and function in mouse and macaque. Human Gene Therapy. PMID 30358434 DOI: 10.1089/hum.2018.193  0.508
2018 Santiago CP, Keuthan CJ, Boye SL, Boye SE, Imam AA, Ash JD. A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 30078764 DOI: 10.1016/J.Ymthe.2018.07.016  0.463
2017 Kanaan NM, Sellnow RC, Boye SL, Coberly B, Bennett A, Agbandje-McKenna M, Sortwell CE, Hauswirth WW, Boye SE, Manfredsson FP. Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS. Molecular Therapy. Nucleic Acids. 8: 184-197. PMID 28918020 DOI: 10.1016/J.Omtn.2017.06.011  0.635
2017 Beltran WA, Cideciyan AV, Boye SE, Ye GJ, Iwabe S, Dufour VL, Marinho LF, Swider M, Kosyk MS, Sha J, Boye SL, Peterson JJ, Witherspoon CD, Alexander JJ, Ying GS, et al. Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28566226 DOI: 10.1016/J.Ymthe.2017.05.004  0.714
2017 Vetter M, Bosco A, Anderson S, Breen K, Romero C, Steele M, Chiodo V, Boye S, Hauswirth W, Tomlinson S. Contribution of microglia and complement activation to glaucoma progression Acta Ophthalmologica. 95. DOI: 10.1111/J.1755-3768.2017.03621  0.484
2016 Choudhury S, Strang CE, Alexander JJ, Scalabrino ML, Lynch Hill J, Kasuga DT, Witherspoon CD, Boye SL, Gamlin PD, Boye SE. Novel Methodology for Creating Macaque Retinas with Sortable Photoreceptors and Ganglion Cells. Frontiers in Neuroscience. 10: 551. PMID 27990105 DOI: 10.3389/Fnins.2016.00551  0.797
2016 Boye SL, Olshevskaya EV, Peshenko IV, McCullough KT, Boye SE, Dizhoor AM. Functional study of two biochemically unusual mutations in GUCY2D Leber congenital amaurosis expressed via adenoassociated virus vector in mouse retinas. Molecular Vision. 22: 1342-1351. PMID 27881908  0.439
2016 Boye S, Alexander JJ, Witherspoon CD, Boye SL, Peterson JJ, Clark M, Sandefer KJ, Girkin CA, Hauswirth WW, Gamlin PD. Highly Efficient Delivery of AAV vectors to the Primate Retina. Human Gene Therapy. PMID 27439313 DOI: 10.1089/hum.2016.085  0.697
2016 Boyd RF, Sledge DG, Boye SL, Boye SE, Hauswirth WW, Komáromy AM, Petersen-Jones SM, Bartoe JT. Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs. Gene Therapy. 23: 400. PMID 27052928 DOI: 10.1038/Gt.2016.10  0.641
2016 Boyd RF, Boye SL, Conlon TJ, Erger KE, Sledge DG, Langohr IM, Hauswirth WW, Komáromy AM, Boye SE, Petersen-Jones SM, Bartoe JT. Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs. Gene Therapy. PMID 27052802 DOI: 10.1038/Gt.2016.31  0.711
2016 Boye SL, Bennett A, Scalabrino ML, McCullough KT, Van Vliet K, Choudhury S, Ruan Q, Peterson J, Agbandje-McKenna M, Boye SE. The Impact of Heparan Sulfate Binding on Transduction of Retina by rAAV Vectors. Journal of Virology. PMID 26865709 DOI: 10.1128/Jvi.00200-16  0.78
2016 Ildefonso CJ, Jaime H, Brown EE, Iwata RL, Ahmed CM, Massengill MT, Biswal MR, Boye SE, Hauswirth WW, Ash JD, Li Q, Lewin AS. Targeting the Nrf2 Signaling Pathway in the Retina With a Gene-Delivered Secretable and Cell-Penetrating Peptide. Investigative Ophthalmology & Visual Science. 57: 372-86. PMID 26842755 DOI: 10.1167/Iovs.15-17703  0.516
2016 Boye SE. A Mini-review: Animal Models of GUCY2D Leber Congenital Amaurosis (LCA1). Advances in Experimental Medicine and Biology. 854: 253-8. PMID 26427419 DOI: 10.1007/978-3-319-17121-0_34  0.431
2016 Scalabrino ML, McCullough KT, Choudhury S, Peterson JJ, Min S, Boye SL, Boye SE. 620. Use of Transgenic Mice to Quantify Transduction Efficiency and Specificity of Novel AAV Vectors in Retina Molecular Therapy. 24: S245-S246. DOI: 10.1016/S1525-0016(16)33428-1  0.82
2015 Ye GJ, Budzynski E, Sonnentag P, Nork TM, Sheibani N, Gurel Z, Boye SL, Peterson JJ, Boye SE, Hauswirth WW, Chulay JD. Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases. Human Gene Therapy. PMID 26603570 DOI: 10.1089/Hum.2015.130  0.705
2015 Boyd RF, Sledge DG, Boye SL, Boye SE, Hauswirth WW, Komáromy AM, Petersen-Jones SM, Bartoe JT. Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs. Gene Therapy. PMID 26467396 DOI: 10.1038/Gt.2015.96  0.711
2015 Lipinski DM, Reid CA, Boye SL, Peterson JJ, Qi X, Boye SE, Boulton ME, Hauswirth WW. Systemic Vascular Transduction by Capsid Mutant Adeno-Associated Virus After Intravenous Injection. Human Gene Therapy. PMID 26359319 DOI: 10.1089/Hum.2015.097  0.559
2015 Scalabrino ML, Boye SL, Fransen KM, Noel JM, Dyka FM, Min SH, Ruan Q, De Leeuw CN, Simpson EM, Gregg RG, McCall MA, Peachey NS, Boye SE. Intravitreal delivery of a novel AAV vector targets ON bipolar cells and restores visual function in a mouse model of complete congenital stationary night blindness. Human Molecular Genetics. PMID 26310623 DOI: 10.1093/Hmg/Ddv341  0.817
2015 Boye SL, Peterson JJ, Choudhury S, Min SH, Ruan Q, McCullough KT, Zhang Z, Olshevskaya EV, Peshenko IV, Hauswirth WW, Ding XQ, Dizhoor AM, Boye SE. Gene Therapy Fully Restores Vision to the All-Cone Nrl(-/-)Gucy2e(-/-) Mouse Model of Leber Congenital Amaurosis-1. Human Gene Therapy. 26: 575-92. PMID 26247368 DOI: 10.1089/Hum.2015.053  0.712
2015 Bogner B, Boye SL, Min SH, Peterson JJ, Ruan Q, Zhang Z, Reitsamer HA, Hauswirth WW, Boye SE. Capsid Mutated Adeno-Associated Virus Delivered to the Anterior Chamber Results in Efficient Transduction of Trabecular Meshwork in Mouse and Rat. Plos One. 10: e0128759. PMID 26052939 DOI: 10.1371/Journal.Pone.0128759  0.683
2015 Ildefonso CJ, Jaime H, Biswal MR, Boye SE, Li Q, Hauswirth WW, Lewin AS. Gene therapy with the caspase activation and recruitment domain reduces the ocular inflammatory response. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 875-84. PMID 25698151 DOI: 10.1038/Mt.2015.30  0.584
2015 Benskey MJ, Kuhn NC, Galligan JJ, Garcia J, Boye SE, Hauswirth WW, Mueller C, Boye SL, Manfredsson FP. Targeted gene delivery to the enteric nervous system using AAV: a comparison across serotypes and capsid mutants. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 488-500. PMID 25592336 DOI: 10.1038/Mt.2015.7  0.623
2015 Ildefonso CJ, Jaime H, Rahman MM, Li Q, Boye SE, Hauswirth WW, Lucas AR, McFadden G, Lewin AS. Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation. Human Gene Therapy. 26: 59-68. PMID 25420215 DOI: 10.1089/Hum.2014.089  0.569
2015 Boye SE. Leber congenital amaurosis caused by mutations in GUCY2D. Cold Spring Harbor Perspectives in Medicine. 5: a017350. PMID 25256176 DOI: 10.1101/cshperspect.a017350  0.441
2015 White ML, Boye SL, Dyka FM, Fransen KM, de Leeuw CN, Simpson EM, Gregg RG, McCall MA, Peachey NS, Boye SE. 498. Optimization of rAAV Targets ON Bipolar Cells and Rescues the nobnyx Mouse Model of X-Linked Congenital Stationary Night Blindness Molecular Therapy. 23: S199. DOI: 10.1016/S1525-0016(16)34107-7  0.525
2014 Boye SE. Insights gained from gene therapy in animal models of retGC1 deficiency. Frontiers in Molecular Neuroscience. 7: 43. PMID 24860425 DOI: 10.3389/fnmol.2014.00043  0.462
2014 de Leeuw CN, Dyka FM, Boye SL, Laprise S, Zhou M, Chou AY, Borretta L, McInerny SC, Banks KG, Portales-Casamar E, Swanson MI, D'Souza CA, Boye SE, Jones SJ, Holt RA, et al. Targeted CNS Delivery Using Human MiniPromoters and Demonstrated Compatibility with Adeno-Associated Viral Vectors. Molecular Therapy. Methods & Clinical Development. 1: 5. PMID 24761428 DOI: 10.1038/Mtm.2013.5  0.679
2014 Boye SE, Huang WC, Roman AJ, Sumaroka A, Boye SL, Ryals RC, Olivares MB, Ruan Q, Tucker BA, Stone EM, Swaroop A, Cideciyan AV, Hauswirth WW, Jacobson SG. Natural history of cone disease in the murine model of Leber congenital amaurosis due to CEP290 mutation: determining the timing and expectation of therapy. Plos One. 9: e92928. PMID 24671090 DOI: 10.1371/Journal.Pone.0092928  0.673
2014 Dyka FM, Boye SL, Ryals RC, Chiodo VA, Boye SE, Hauswirth WW. Cone specific promoter for use in gene therapy of retinal degenerative diseases. Advances in Experimental Medicine and Biology. 801: 695-701. PMID 24664760 DOI: 10.1007/978-1-4614-3209-8_87  0.669
2014 Dyka FM, Boye SL, Chiodo VA, Hauswirth WW, Boye SE. Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A. Human Gene Therapy Methods. 25: 166-77. PMID 24568220 DOI: 10.1089/Hgtb.2013.212  0.661
2013 Conlon TJ, Deng WT, Erger K, Cossette T, Pang JJ, Ryals R, Clément N, Cleaver B, McDoom I, Boye SE, Peden MC, Sherwood MB, Abernathy CR, Alkuraya FS, Boye SL, et al. Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Human Gene Therapy. Clinical Development. 24: 23-8. PMID 23692380 DOI: 10.1089/Humc.2013.037  0.705
2013 Kay CN, Ryals RC, Aslanidi GV, Min SH, Ruan Q, Sun J, Dyka FM, Kasuga D, Ayala AE, Van Vliet K, Agbandje-McKenna M, Hauswirth WW, Boye SL, Boye SE. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. Plos One. 8: e62097. PMID 23637972 DOI: 10.1371/Journal.Pone.0062097  0.718
2013 Jiang L, Li TZ, Boye SE, Hauswirth WW, Frederick JM, Baehr W. RNAi-mediated gene suppression in a GCAP1(L151F) cone-rod dystrophy mouse model. Plos One. 8: e57676. PMID 23472098 DOI: 10.1371/Journal.Pone.0057676  0.655
2013 Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 509-19. PMID 23358189 DOI: 10.1038/Mt.2012.280  0.636
2013 Lopes VS, Boye SE, Louie CM, Boye S, Dyka F, Chiodo V, Fofo H, Hauswirth WW, Williams DS. Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus. Gene Therapy. 20: 824-33. PMID 23344065 DOI: 10.1038/Gt.2013.3  0.744
2013 Boye SL, Peshenko IV, Huang WC, Min SH, McDoom I, Kay CN, Liu X, Dyka FM, Foster TC, Umino Y, Karan S, Jacobson SG, Baehr W, Dizhoor A, Hauswirth WW, ... Boye SE, et al. AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Human Gene Therapy. 24: 189-202. PMID 23210611 DOI: 10.1089/Hum.2012.193  0.708
2013 Kay CN, Ryals RC, Aslanidi GV, Min SH, Ruan Q, Sun J, Dyka FM, Kasuga D, Ayala AE, Van Vliet K, Agbandje-McKenna M, Hauswirth WW, Boye SL, Boye SE. Correction: Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors Plos One. 8. DOI: 10.1371/Annotation/99Ee1789-A658-4Fb0-8593-40A40E9F344A  0.595
2012 Boye SE, Alexander JJ, Boye SL, Witherspoon CD, Sandefer KJ, Conlon TJ, Erger K, Sun J, Ryals R, Chiodo VA, Clark ME, Girkin CA, Hauswirth WW, Gamlin PD. The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Human Gene Therapy. 23: 1101-15. PMID 22845794 DOI: 10.1089/Hum.2012.125  0.741
2012 Yu H, Koilkonda RD, Chou TH, Porciatti V, Ozdemir SS, Chiodo V, Boye SL, Boye SE, Hauswirth WW, Lewin AS, Guy J. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model. Proceedings of the National Academy of Sciences of the United States of America. 109: E1238-47. PMID 22523243 DOI: 10.1073/Pnas.1119577109  0.61
2011 Jiang L, Zhang H, Dizhoor AM, Boye SE, Hauswirth WW, Frederick JM, Baehr W. Long-term RNA interference gene therapy in a dominant retinitis pigmentosa mouse model. Proceedings of the National Academy of Sciences of the United States of America. 108: 18476-81. PMID 22042849 DOI: 10.1073/Pnas.1112758108  0.677
2011 Boye SL, Conlon T, Erger K, Ryals R, Neeley A, Cossette T, Pang J, Dyka FM, Hauswirth WW, Boye SE. Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Investigative Ophthalmology & Visual Science. 52: 7098-108. PMID 21778276 DOI: 10.1167/Iovs.11-7867  0.694
2011 Ryals RC, Boye SL, Dinculescu A, Hauswirth WW, Boye SE. Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines. Molecular Vision. 17: 1090-102. PMID 21552473  0.626
2011 Doroudchi MM, Greenberg KP, Liu J, Silka KA, Boyden ES, Lockridge JA, Arman AC, Janani R, Boye SE, Boye SL, Gordon GM, Matteo BC, Sampath AP, Hauswirth WW, Horsager A. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1220-9. PMID 21505421 DOI: 10.1038/Mt.2011.69  0.692
2011 Pang JJ, Dai X, Boye SE, Barone I, Boye SL, Mao S, Everhart D, Dinculescu A, Liu L, Umino Y, Lei B, Chang B, Barlow R, Strettoi E, Hauswirth WW. Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 234-42. PMID 21139570 DOI: 10.1038/Mt.2010.273  0.714
2010 Boye SE, Boye SL, Pang J, Ryals R, Everhart D, Umino Y, Neeley AW, Besharse J, Barlow R, Hauswirth WW. Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. Plos One. 5: e11306. PMID 20593011 DOI: 10.1371/Journal.Pone.0011306  0.694
2010 Beltran WA, Boye SL, Boye SE, Chiodo VA, Lewin AS, Hauswirth WW, Aguirre GD. rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters. Gene Therapy. 17: 1162-74. PMID 20428215 DOI: 10.1038/Gt.2010.56  0.739
2010 Pang J, Boye SE, Lei B, Boye SL, Everhart D, Ryals R, Umino Y, Rohrer B, Alexander J, Li J, Dai X, Li Q, Chang B, Barlow R, Hauswirth WW. Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. Gene Therapy. 17: 815-26. PMID 20237510 DOI: 10.1038/Gt.2010.29  0.657
2007 Roman AJ, Boye SL, Aleman TS, Pang JJ, McDowell JH, Boye SE, Cideciyan AV, Jacobson SG, Hauswirth WW. Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis. Molecular Vision. 13: 1701-10. PMID 17960108  0.581
Show low-probability matches.